Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Actinogen Medical ( (AU:ACW) ) has provided an update.
Actinogen Medical Limited has applied to the ASX for quotation of 4,000,000 new ordinary fully paid shares, which are scheduled to be issued and commence trading on 23 December 2025 under the ticker ACW. The additional securities, arising from the exercise or conversion of existing options or other convertible instruments, modestly expand the company’s share base and may provide incremental capital and liquidity, with implications for existing shareholders through potential dilution and for the company’s financial flexibility as it advances its business activities.
The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited is an Australian biotechnology company listed on the ASX under the code ACW. The company operates in the medical and life sciences sector, focusing on the development of pharmaceutical and therapeutic products.
Average Trading Volume: 4,290,223
Technical Sentiment Signal: Buy
Current Market Cap: A$191M
For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.